Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026 [TheStreet.com]
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: TheStreet.com
PR Newswire NEW YORK, April 21, 2026 Analysis of longer-term pooled data from TRUST-I and TRUST-II demonstrated nearly 50 months median duration of response and 46.1 months median progression-free survival in TKI-naïve patients IBTROZI also demonstrated a high overall response rate in TKI-naïve patients at 89.8% Long-term pooled data highlighted in oral and poster presentations at AACR, and TRUST-I data simultaneously published in the Journal of Clinical Oncology , reinforce IBTROZI's manageable safety profile, with low rates of neurologic side effects and no new safety signals IBTROZI demonstrated robust CNS activity, with an intracranial response rate of 76.5% in TKI-naïve patients and 65.6% in TKI-pretreated patients with brain metastases Preclinical data presented at AACR showed taletrectinib's potential for suppressing TRKB-mediated lung cancer cell migration NEW YORK April 21, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused o
Show less
Read more
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026 [Yahoo! Finance]Yahoo! Finance
- /U P D A T E -- Nuvation Bio Inc./ [TheStreet.com]TheStreet.com
- Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026PR Newswire
- Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026 [TheStreet.com]TheStreet.com
- Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026PR Newswire
NUVB
Earnings
- 3/2/26 - In-Line
NUVB
Sec Filings
- 4/21/26 - Form 4
- 4/21/26 - Form 4
- 4/21/26 - Form DEFA14A
- NUVB's page on the SEC website